Skip to content

Pentadeca arginate (PDA)

PeptidespeptideEarly stage

Availability Not yet prescribable · sold for research use only

What it is

Pentadeca arginate, usually shortened to PDA, is the arginate salt of the same fifteen amino acid sequence as BPC-157. Vendors describe the salt form as more stable in solution. It is a repackaging of a known peptide rather than a new discovery, and understanding that is the whole story of why it exists.

Why people take it

PDA became visible in 2024 for a commercial reason rather than a scientific one. When FDA action in 2023 put BPC-157 out of reach for compounding pharmacies, providers needed something to offer the people asking for a repair peptide, and a renamed salt of the same sequence filled the gap. Buyers want what they wanted from BPC-157: faster recovery from a soft-tissue injury.

How it's delivered

Some clinics advertise PDA as a subcutaneous injection or as oral capsules for gut-focused use; it is not an approved drug and does not appear on FDA's lists of substances for compounding. Because PDA is a salt of an unapproved substance, the same sourcing questions apply as to any gray-market peptide: which pharmacy made it, what was tested, and what the certificate of analysis actually shows. Pentadeca arginate is not covered by HHS's draft October 2026 interim compounding policy, which names BPC-157 acetate, not its analogs.

Where the evidence stands

There is no published human trial of pentadeca arginate. Every benefit attributed to it is borrowed from BPC-157's animal literature on the argument that the active sequence is identical, which also means it inherits BPC-157's missing human evidence. Its regulatory position is weaker still: PDA does not appear anywhere on FDA's nominated bulk substance lists. FDA's Pharmacy Compounding Advisory Committee voted in favor of listing BPC-157 in July 2026, as HHS's October 2026 policy records; that review did not name PDA. The stability advantage over BPC-157 is a manufacturer claim, not a demonstrated clinical difference. Anti-doping rules that reach BPC-157 as a non-approved substance reach this form too.

Estimated cost

  • No approved or lawfully compounded product, so no reference price
  • Not covered by insurance

Who offers it

We don't list providers for pentadeca arginate: there is no approved product and no lawful compounding route, so there is nothing we can point you to. Anything sold online is unregulated.

Go deeper

The compound page, Pentadeca arginate in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Muscle Repair and Injury Recovery, covers the compounding-rule history that produced this compound.

Longevity.io is for educational purposes only and is not medical advice. Whether a repair peptide belongs in a plan is a conversation for a clinician who knows the whole picture. Confirm eligibility, product source, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint